Landos Biopharma Inc (LABP) Stock
LABP is no longer traded. Landos Biopharma was delisted from the Nasdaq in May 2024.
Prices on this page are historical; the last trade was May 23, 2024 at $22.93.
Landos Biopharma stock price history
LABP final trading statistics
- Final close
- $22.93
- Final trading day
- May 23, 2024
- Market cap at delisting
- $71.68M
- Shares outstanding
- 3.13M
- Final 52-week range
- $0.31 – $22.94
- Avg. volume (final 3 mo.)
- 25,822
- All-time high (split-adj.)
- $162.60 · Mar 2021
- All-time low (split-adj.)
- $2.15 · Nov 2022
- Return since IPO
- -80.9%
- Beta
- 0.14
- Book value / share
- $7.43
- Price / book
- 3.09
Landos Biopharma annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $0.00 | -$21.9M | -$2.65 |
| FY2022 | $0.00 | -$38.0M | -$0.98 |
| FY2021 | $18.00M | -$38.2M | -$0.98 |
| FY2020 | $18.00M | -$30.1M | -$1.62 |
| FY2019 | $0.00 | -$13.9M | -$1.02 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Landos Biopharma Inc
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia. As of May 23, 2024, Landos Biopharma, Inc. operates as a subsidiary of AbbVie Inc.
Landos Biopharma stock FAQ
What happened to Landos Biopharma stock?
Landos Biopharma stock was delisted from the Nasdaq. Its final close was $22.93 on May 23, 2024.
Is LABP stock still trading?
No. LABP was delisted from the Nasdaq in May 2024 and no longer trades on a U.S. exchange.
What was the last price of LABP stock?
LABP closed at $22.93 on its final trading day, May 23, 2024, for a market value of about $71.68M.
What were Landos Biopharma's revenue and earnings in its last full fiscal year?
Landos Biopharma reported revenue of $0.00 and net income of -$21.9M in fiscal 2023, its last full year as a public company.
When did Landos Biopharma go public?
Landos Biopharma Inc stock began trading on February 4, 2021.